(CercleFinance.com) – Aelis Farma, a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases, announces the initiation of coverage of its title by Bryan Garnier & Co.
In its introductory study entitled ‘Aelis in Wonderland’, published on March 29, 2022, Bryan Garnier & Co begins monitoring the stock with a recommendation to buy and values the company at 21 euros per share.
Copyright © 2022 CercleFinance.com. All rights reserved.
The information and analyzes disseminated by Cercle Finance only constitute a decision-making aid for investors. The responsibility of Cercle Finance cannot be held directly or indirectly following the use of information and analyzes by readers. It is recommended that any uninformed person consult a professional adviser before any investment. This indicative information does not in any way constitute an incitement to sell or a solicitation to buy.
Did you like this article ? Share it with your friends with the buttons below.
